REQUEST A DEMO
Total
USD $0.00
Search more companies

Nang Kuang Pharmacecutical Co., Ltd (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Architectural, Engineering, and Related Services
Full name: Nang Kuang Pharmacecutical Co., Ltd Profile Updated: February 21, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Chinese Download a sample report

In 1963, Nan Kuang photochemical laboratory was founded in Tainan. New plant was completed in 1973, Xinhua Town, Tainan County, and the company restructured to be Nang Kuang Pharmaceutical Co., Ltd. It is approved by the Government in 1985 as an integrated pharmaceutical GMP, then Computer and Information Centre was set up. In 1986, Ministry of Economic Affairs Investment Commission approved the technical cooperating between Kobayashi Pharmaceutical Industries Ltd. in Japan and Nan Kuang. In 1987, 1, the company authorized Kaohsiung Medical College to do research project for the company's products on "within the powder injection determination of the child" and "large-scale output Note mixture of liquid injection Hing small feasibility". 2. The company purchased automatic amino acid analyzer to study the development of total parental nutrition infusion fluid. In 1988, 1, Huajing Kang Pharmacy Foundation commissioned the National Taiwan University for the medium-sized company's products to do "Health and body D with a rate (Bioavailability)" and "bioequivalent (Bioequivalence)" test of the project research. 2, The Company established Taipei Office because of the expansion of overseas direct marketing to expand the business. In 1990, percutaneous absorption test animal. In 1991, the company implemented quality improvement program (QIP) and human resources self-assessment, investigation and staff multi-specialty training programs. In 1992, Pharmaceutical preparations for the planning and building science and technology research and development building were completed. In 1993 1,water pollution prevention plan to implement waste reduction programs, 2 employ overseas scholars to return based oral sustained-release formulations and transversal formulations of whole dressed R & D center. 1996, from West Germany to introduce China's first large-scale manufacture of infusion bags filled with fully automatic soft- machine, the Ministry of Finance for the Securities and Exchange Commission approved the IPO, for surplus capital increase. 2002, the company imported New HUETTLIN granulator from Germany.

Headquarters
1001, Chung Shan Road, Sinhua Chen
Tainan City; Tainan City;

Contact Details: Purchase the Nang Kuang Pharmacecutical Co., Ltd report to view the information.

Website: http://www.nangkuang.com.tw

Basic Information
Total Employees:
Purchase the Nang Kuang Pharmacecutical Co., Ltd report to view the information.
Outstanding Shares:
Purchase the Nang Kuang Pharmacecutical Co., Ltd report to view the information.
Financial Auditors:
Purchase the Nang Kuang Pharmacecutical Co., Ltd report to view the information.
Incorporation Date:
August 20, 1973
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
5.42%
Purchase this report to view the information.
3.49%
Purchase this report to view the information.
2.26%
Purchase this report to view the information.
0.04%
Purchase this report to view the information.
Subsidiaries
Nang Kuang Pharm Sdn.Bhd. (Malaysia)
100%
Company Performance
Financial values in the chart are available after Nang Kuang Pharmacecutical Co., Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
21.99%
Total operating revenue
22.51%
Operating profit (EBIT)
35.14%
EBITDA
10.49%
Net Profit (Loss) for the Period
22.59%
Total assets
13.63%
Total equity
7.26%
Operating Profit Margin (ROS)
1.61%
Net Profit Margin
0.07%
Return on Equity (ROE)
1.21%
Debt to Equity Ratio
4.05%
Quick Ratio
-0.09%
Cash Ratio
-0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?